FDA Approves Manufacturing Change for Pfizer COVID-19 Vaccine

12/16/21 — The FDA approved a manufacturing change for Comirnaty (COVID-19 Vaccine, mRNA) to include a formulation that uses a different buffer, which helps maintain a vaccine’s pH and stability. This new formulation is more stable at refrigerated temperatures for longer periods of time, permitting greater flexibility for vaccination providers. Read the FDA approval letter.